available everywhere, and is explained below. NAC has many potential beneficial properties... some of which you can read about here:
http://www.wholehealthmd.com/refshelf/substances_view/1,1525,809,00.htmlhttp://www.lef.org/magazine/mag2003/may2003_report_pet_02.htmlNAC is a form of the amino acid, cysteine, with multiple kidney-protective actions. The research on what NAC can do for the kidney (and the liver) is scientifically well-documented. In one recent study, researchers in Italy demonstrated that NAC normalizes creatinine levels in rodents with kidney failure. It reverses inflammation and restores filtration. Similar findings are reported by French researchers when NAC is given as a pretreatment before experimental kidney damage in rats. Without NAC, there is a 68% reduction in the ability of the kidneys to do their job. With it, the loss of kidney function is only 29%. A third study confirms that an infusion of NAC before and after experimental kidney damage doubles the kidney filtration rate. NAC is strong medicine for the kidneys. It has no adverse side effects, even when small animals like cats are given a human dose.
http://dnrc.niddk.nih.gov/dnrc/Program_93-95/NEI.htmAge-related cataract and macular degeneration are the major causes of visual impairment and blindness in the aging U.S. population. The NEI supports research on the role of general nutrition and of certain micronutrients-in particular, vitamins and trace minerals with antioxidant capabilities-on the development and worsening of these two eye disorders. NEI-supported scientists also are evaluating the effect of nutritional factors on other visual disorders, such as retinopathy of prematurity, cystinosis, retinitis pigmentosa, and diabetic retinopathy.
http://www.bloodjournal.org/cgi/content/full/91/11/4373Next, we wanted to test the efficacy of reducing agents, or antioxidants, which are in clinical use for other purposes. Cysteamine bitartrate converts cystines to cysteines and cysteine-cysteamine mixed disulfides. It has been approved by the Food and Drug Administration (FDA) for the treatment of
nephropathic cystinosis and appears to maintain normal renal functions in patients receiving the drug.20 Cysteamine was ineffective in blocking ISC formation (at 1 to 50 mmol/L) and actually caused increases in the number of ISCs at higher concentrations (150 mmol/L and 200 mmol/L) (data not shown).
Succimer (meso 2,3-dimercaptosuccinic acid) and dimercaprol are used clinically as chelators of heavy metals, such as lead.21 Succimer was ineffective at blocking ISC formation in vitro (at 1 to 30 mmol/L) and again caused increases in ISCs at concentrations of 100 to 200 mmol/L (data not shown). Dimercaprol caused a statistically significant decrease in ISCs at 10 µm concentration (-20.5%), but at higher concentrations (0.1 to 1.0 mmol/L) caused increases in percent ISCs (data not shown).
NAC is an antioxidant and is converted intracellularly to L-cysteine, which is a precursor to reduced glutathione. We felt that the combined activities of this drug might make it particularly efficacious in blocking ISC formation in vitro. As shown in Table 2, NAC caused statistically significant decreases in percent ISCs at concentrations of 250 µmol/L to 20 mmol/L NAC. At 20 mmol/L NAC, there was a reduction of 35.7% ISCs. NAC (20 mmol/L) had no effect on cell lysis during the 16 hours of cycling, as evidenced by identical concentrations of hemoglobin (measured by absorbance at 430 nm) in the incubation mixtures ± NAC (data not shown). Figure 1 shows a typical smear of ISCs formed in vitro in the presence (Fig 1C) or absence (Fig 1B) of 20 mmol/L NAC.
http://www.naturalopinion.com/nmp/nmp5/Nacecyst.htmToxicity and Side Effects:
* Genetic disorder cystinosis, or Fanconi's, causes the body to build up harmful levels of L-cystine (not cysteine)
Copyright 1998 - 2005 by L. Vicky Crouse, ND and James S. Reiley, ND. All rights reserved (ISSN 1527-0661).